港股异动 | 锦欣生殖(1951.HK)续涨逾4% 拟收购武汉黄浦医院75%股权
格隆汇7月2日丨本周二(30日)大涨12.1%的锦欣生殖(1951.HK)今日续涨,现报12.18港元,涨4.37%,暂成交3.6亿港元,最新总市值295亿港元。公司周一(29日)晚间发公告称,附属公司四川锦欣拟收购武汉黄浦医院75%股权。瑞信最新发研报认为交易条件吸引,公司可借此进军辅助生育(IVF)服务渗透率较低、市场分散的湖北地区。收购为公司提供长期增长机会,加上其行业领先地位,维持“跑赢大市”评级,目标价升至13.54港元。招银国际亦上调其目标价至14.4港元,维持“买入”评级。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.